Aurinia Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is AUPH moving today?
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for AUPH.
AUPH insider activity
Aurinia Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net buying: $28.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-06-02 | TANG KEVIN | Insider | buy | $1.65 | 10,000 | 10,000 | $17K | SEC Form 4 |
| 2026-06-02 | 2026-06-02 | TANG KEVIN | Insider | buy | $15.28 | 206,005 | 13,044,106 | $3.1M | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | TANG KEVIN | Insider | buy | $15.34 | 99 | 12,838,101 | $2K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | TANG KEVIN | Insider | buy | $15.28 | 343,521 | 12,838,002 | $5.2M | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | TANG KEVIN | Insider | buy | $15.31 | 262,682 | 12,494,481 | $4.0M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 27 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAUPH contract awards, year to date.
Public federal awards linked to this ticker.
AUPH lobbying filings, year to date.
Registered lobbying filings matched to Aurinia Pharmaceuticals Inc.